• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

    11.11 +0.03 (+0.23%)
    Streaming Delayed Price Updated: 11:02 AM EDT, Jul 23, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Verve Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    3 Bullish Biotech Stocks With Explosive Growth Trends
    These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies 
    Via MarketBeat
    Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
    Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO. 
    Via MarketBeat
    Topics Economy Stocks
    VERVE THERAPEUTICS INC (NASDAQ:VERV) - A High-Growth Biotech Stock Meeting Minervini's Criteria
    VERVE THERAPEUTICS (VERV) is a high-growth biotech stock meeting Minervini's Trend Template criteria, with strong revenue growth, bullish technicals, and upward earnings revisions. 
    Via Chartmill
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
    Via The Motley Fool
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLP, VERV, CVAC on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
    Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
    Via Benzinga
    This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
    Via Benzinga
    Market Monitor News June 18 (Jabil, Reddit & Verve Therapeutics UP - Solar Stocks First Solar, Sunrun & SolarEdge DOWN)
    Wall Street stays cool despite geopolitical tension, weak retail data, and a meltdown in solar stocks. 
    Via Chartmill
    5 Analysts Assess Verve Therapeutics: What You Need To Know
    Via Benzinga
    These stocks are moving in today's session
    Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
    Via Chartmill
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Which stocks are moving on Tuesday?
    Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
    Via Chartmill
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Why Verve Therapeutics Stock Is Skyrocketing Today
    Via The Motley Fool
    Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Which stocks are gapping on Tuesday?
    The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
    Via Chartmill
    Power Metallic (TSX.V: PNPN) Secures Largest Saudi License Amid June 2025 Gold Surge – Material Gains & More Stocks Inside
    Via AB Newswire
    Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’
    Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share,... 
    Via Stocktwits
    Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
    The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
    Via Investor's Business Daily
    Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
    Via Benzinga
    Get insights into the top gainers and losers of Tuesday's pre-market session.
    Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
    Via Chartmill
    Shareholder Alert: The Ademi Firm Investigates Whether Verve Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
    From Ademi & Fruchter LLP
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition
    Eli Lilly is acquiring Verve Therapeutics to strengthen its cardiovascular pipeline with a gene-editing drug targeting PCSK9-linked conditions. 
    Via Benzinga
    Why Lennar Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Verve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover Talks
    The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies. 
    Via Stocktwits
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    12 13 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.